NYSEMKT: AGEAgex Therapeutics Inc Stock
$0.68+0.00 (+0%)
Updated Sep 29, 2023
AGE Price
$0.68
Fair Value Price
N/A
Market Cap
$25.81M
52 Week Low
$0.37
52 Week High
$1.00
P/E
-2.27x
P/B
-1.16x
P/S
941.61x
PEG
N/A
Dividend Yield
N/A
Revenue
$36.00k
Earnings
-$11.08M
Gross Margin
66.7%
Operating Margin
-20,252.78%
Profit Margin
-30,788.9%
Debt to Equity
-1.56
Operating Cash Flow
-$6M
Beta
1.11
Next Earnings
Nov 13, 2023
Ex-Dividend
N/A
Next Dividend
N/A
AGE Overview
AgeX Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in Alameda, California and currently employs 12 full-time employees. The firm is focused on the development and commercialization of therapeutics targeting human aging. Its induced Tissue Regeneration (iTR) technology is based telomerase-mediated cellular immortality and regenerative biology. Its pipeline includes two cell-based, two drug-based therapeutic products, online database products and research products. The Company’s AGEX-BAT1 is its cell therapy product candidate that is being developed for the treatment of certain age-related metabolic disorders, such as Type II (adult-onset) diabetes. AGEX-VASC1 is its cell-based therapy that is designed to restore vascular support in aged ischemic tissues such as the aging heart. AGEX-iTR1547 is its drug-based formulation developed to restore regenerative potential in an array of aged tissues afflicted with degenerative disease using its proprietary iTR technology. Renelon is its iTR product candidate designed to promote scar less tissue repair.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how AGE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AGE is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
AGE is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
AGE's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more AGE due diligence checks available for Premium users.
Be the first to know about important AGE news, forecast changes, insider trades & much more!
AGE News
Valuation
AGE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.27x
Industry
13.67x
Market
12.37x
AGE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-1.16x
Industry
5.09x
AGE's financial health
Profit margin
Revenue
$9.0k
Net Income
-$2.7M
Profit Margin
-29,655.6%
AGE's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
AGE's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$12.3M
Liabilities
$34.6M
Debt to equity
-1.56
AGE's short-term liabilities ($24.51M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AGE's long-term liabilities ($10.07M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AGE's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AGE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.0M
Investing
$0.0
Financing
$2.0M
AGE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AGE vs Biotech Stocks
Agex Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.